What the FDA labels say about taking them together
Abatacept and infliximab
Infliximab's FDA label of August 28, 2026 names abatacept in its drug interactions section; the abatacept label PlainMeds reads does not name infliximab. The infliximab label: “An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit.”
Check it at the source: the abatacept FDA label on DailyMed (effective November 13, 2025, E.R. Squibb & Sons, L.L.C.); the infliximab FDA label on DailyMed (effective August 28, 2026).
What does the abatacept label say about infliximab?
Abatacept's label (effective November 13, 2025) does not name infliximab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (ORENCIA), E.R. Squibb & Sons, L.L.C., effective November 13, 2025 (SPL set 0836c6ac-ee37-5640-2fed-a3185a0b16eb), via openFDA; the full label on DailyMed
What does the infliximab label say about abatacept?
Infliximab label, drug interactionsAn increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit.
Infliximab label, warnings and precautionsIn clinical studies, concurrent administration of TNF blockers and abatacept have been associated with an increased risk of infections including serious infections compared with TNF blockers alone, without increased clinical benefit.
Source: FDA drug label (Renflexis), Organon LLC, effective August 28, 2026 (SPL set dbf738c4-3fac-4422-a9d8-51d9c83a8789), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Abatacept | Infliximab | |
|---|---|---|
| Labeled for | Rheumatoid arthritis | Rheumatoid arthritis, Crohn's disease and ulcerative colitis |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $1,469.23 per mL 125 mg/mL syringe | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once